The Trump Administration may finally be taking serious action against the pharmaceutical industry in a bid to cut down heavily inflated US drug prices, while using the FDA to speed and simplify generic and biosimilar approvals. Additionally, a wave of lawsuits targeting big pharma for their role in the opioid crisis is inching closer to court and, possibly, the largest ever civil litigation settlement agreement in U.S. history . . .

To read more, sign up for aFree 30-Day Trial   of MRP's research, orLog In